ASMBAssembly Biosciences, Inc.
$22.80-4.4% 1Y
$22.80
$22.1952 weeks$38.50
ASMB in its own filings
ASMB's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
309
Events found in the filings · across 893 filings · the record starts in 2010
- Hard flags
- 3
Hard flags
- Most recent filing
- Aug 14, 2026
Most recent filing · Form 8-K/A
- Record starts
- Aug 16, 2010
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Change in certifying accountant2 occurrences
- 2015-05-11
- Late periodic report3 occurrences
- 2014-11-14
- Delisting notice / listing-rule failurehistorical
- 2023-09-29
- SEC comment-letter activity26 occurrences
- 2026-03-25
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 14, 2026Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates.Earnings release · press release
- Aug 13, 2026Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates.Acquisition or disposition completed · press release
- Jun 5, 2026Amendment No. 3 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. (the "Company") Annual Meeting of Stockholders held on June 4, 2026, (the "Annual Meeting"), the Company's stockholders approved Amendment No. 3 ("Amendment No. 3") to the Assembly Biosciences, Inc. Amended and Restated …Director or officer change · Form 8-K
- May 26, 2026On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto (the "Underwriters"), in …Material agreement entered · Form 8-K
- May 22, 2026The Company has plans to expand the clinical development of 6250, its oral entry inhibitor candidate for chronic HDV infection, into PBC and PSC, broadening the program into cholestatic liver diseases. 6250 is currently being evaluated for chronic HDV infection and has completed a Phase 1a clinical trial in healthy …Regulation FD disclosure · Form 8-K
- May 7, 2026Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release
- Mar 30, 2026On March 24, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) approved a new cash bonus plan, the 2026 Corporate Bonus Plan (the “Plan”)Director or officer change · Form 8-K
- Mar 19, 2026Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights.Earnings release · press release
- Dec 8, 2025ABI-1179 The Company announced interim results from the 1179 Study. For the powered antiviral endpoint, HSV type 2 ("HSV-2") shedding rate, highly potent antiviral activity was observed with a 98% reduction compared to placebo (p<0.01) over the 29-day evaluation period in the cohort evaluating a 50 mg weekly dose.Regulation FD disclosure · Form 8-K
- Nov 10, 2025Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…